ProfileBack to List
NYU Stern School of Business, Global Economics Group
- Principal, Global Economics Group
- Adjunct Associate Professor, NYU Stern School of Business
New York, New York
Experience & Areas of Interest:
Dr. Rosa M. Abrantes-Metz's experience includes work in consulting and banking, as well as in government. Her main areas of specialization are econometrics, financial economics, monetary economics, and applied industrial organization. Dr. Abrantes-Metz is an Associate Adjunct Professor at Leonard N. Stern School of Business, New York University, where she teaches industrial economics. She has taught econometrics at the department of economics at the University of Chicago, and various other fields of economics at Universidade Catolica Portuguesa, in Lisbon, Portugal.
Since working as a staff economist at the Federal Trade Commission, Dr. Abrantes-Metz continued serving as a consultant for special projects with the Commission's Bureau of Economics. She is the author of several articles on econometric methods, conspiracies and manipulations, gasoline, pharmaceuticals and healthcare, event studies, and has published in many peer-reviewed journals. Dr. Abrantes-Metz is a co-drafter of the chapter on the role of the economic expert in proving conspiracy cases under federal antitrust laws, a recent volume by the American Bar Association, and a contributor to other books on antitrust and international arbitration with a focus on event studies.
Dr. Abrantes-Metz has developed numerous screens for conspiracies and manipulations, and is a pioneer in the field, contributing to the increased adoption of these empirical methods. She has flagged potential anti-competitive behavior preceding large-scale worldwide investigations, such as the alleged Libor conspiracy and manipulation (LIBOR Manipulation? (2008) and Tracking the Libor Rate (2010)). At the time the first investigations on Libor surfaced, Dr. Abrantes-Metz's work was covered by the Wall Street Journal and the Financial Times. Her screens are used by competition authorities worldwide and also by defendants.
In pharmaceuticals, she has co-developed a model to estimate the likelihood of drugs failing and succeeding each of the clinical stages of the Food and Drug Administration, and their expected durations in each of these phases. This model has become one of the two most used by industry analysts to value pharmaceutical and biotechnology pipelines. Her research on pharmaceuticals and conspiracies has been discussed in books on how to value pharmaceutical and biotechnology companies, and on publications pertaining to healthcare, intellectual property and cartels. She has presented her work to competition authorities all over the world. Dr. Abrantes-Metz has provided testimony related to alleged bid-rigging and price-fixing, and in international arbitration on the valuation of expropriated assets.
- 2002, University of Chicago, PhD
- 1997, University of Chicago, MA
- 1996, Universitat Pompeu Fabra, MA
- Licenciatura in Economics from Universidade Catolica Portuguesa
In addition to writing the papers listed below, Dr. Abrantes-Metz has taught classes on econometrics for the CPI Learning Center. You can view these here.
You can contact me at Rabrantesfirstname.lastname@example.org
- Recent Successes of Screens for Conspiracies and Manipulations: Why Are There Still Skeptics?” - Antitrust Chronicle - Oct 28, 2014
- Health Care Benefits vs. Costs: Are We Making the Right Choices? - Antitrust Chronicle - Sep 26, 2014
- Did Credit Rating Agencies Cause the European Sovereign Debt Crisis? - Antitrust Chronicle - Jan 28, 2014
- Is There Misdiagnosis and Mistreatment in the Market for Credit Ratings? - Antitrust Chronicle - Dec 17, 2013
- Is There Misdiagnosis and Mistreatment in the Market for Credit Ratings? - Antitrust Chronicle - Nov 25, 2013
- Libor, Screening & Reform - Library Articles - Jan 08, 2013
- Will Wheatleyâ€™s Recommendations Fix the LIBOR? - Library Articles - Dec 27, 2012
- How to Fix the Libor - Library Articles - Dec 27, 2012
- Lessons from LIBOR for Detection and Deterrence of Cartel Wrongdoing - Antitrust Chronicle - Nov 27, 2012
- Will The Wheatley Recommendations Fix LIBOR? - Antitrust Chronicle - Nov 27, 2012
- Why a Reduction in Health Care Costs Per Se May be a Misleading Policy Objective - Antitrust Chronicle - Jul 27, 2012
- CPI Cartel Column - Note from the Editor - Library Articles - Jul 20, 2012
- Why and How Should the Libor Be Reformed? - Antitrust Chronicle - Jul 16, 2012
- Antitrust and Regulation: Credit Rating Agencies - News - Jun 29, 2012
- Screens for Conspiracies and Their Multiple Applications (reprint) - CPI Article - Jun 18, 2012
- Interview: Update on "Screens for Conspiracies and Their Multiple Applications" - CPI Article - Jun 16, 2012
- How Far Can Screens Go in Distinguishing Explicit from Tacit Collusion? New Evidence on the Libor Setting - Antitrust Chronicle - Mar 13, 2012
- Why and How to Use Empirical Screens in Antitrust Compliance - Antitrust Chronicle - Feb 14, 2012
- Design and Implementation of Screens and Their Use by Defendants - Antitrust Chronicle - Sep 28, 2011
- Libor Litigation and the Role of Screening: The Need for Enhanced Compliance Programs - Antitrust Chronicle - Jul 25, 2011
- Screens for Conspiracies and Their Multiple Applications - CPI Article - Nov 04, 2010